SCHEMBL24258023

SCHEMBL24258023

O=c1ccc(-c2noc(Cc3cc(F)cc(F)c3)n2)c[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.43
S1PR3 Q99500 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
ERCC1 P07992 1/20 0.40
ERCC4 Q92889 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
HTT P42858 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 3/20 0.39
MAPK1 P28482 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
SIRT2 Q8IXJ6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258084 0.83 S1PR1 (0.58) S1PR1S1PR3SMN1; SMN2NPC1RAB9A
SCHEMBL24258072 0.81 MAPK1 (0.58) ERCC1ERCC4SMN1; SMN2RAB9AHTT
SCHEMBL24258048 0.81 TDP1 (0.57) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL24258053 0.81 ERCC1 (0.49) S1PR1ERCC1ERCC4SMN1; SMN2NPC1
SCHEMBL24258021 0.80 ERCC1 (0.48) S1PR1ERCC1ERCC4SMN1; SMN2NPC1
SCHEMBL24258039 0.79 ERCC1 (0.45) S1PR1S1PR3ERCC1ERCC4SMN1; SMN2
SCHEMBL26005131 0.76 ERCC1 (0.43) ERCC1ERCC4SMN1; SMN2RAB9AHTT
SCHEMBL24258036 0.75 DAO (0.41) SMN1; SMN2NPC1RAB9AHTTLMNA
SCHEMBL26004727 0.74 MAPT (0.47) ERCC1ERCC4SMN1; SMN2NPC1RAB9A
SCHEMBL26006746 0.74 ERCC1 (0.39) S1PR1ERCC1ERCC4SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 S1PR1 4154/4885S1PR3 4275/4885CHRM2 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.